PhaseBio Pharmaceuticals, Inc.

OTCPK:PHAS.Q Stock Report

Market Cap: US$49.0

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

PhaseBio Pharmaceuticals Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Jonathan Mow

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure9.5yrs
CEO ownershipn/a
Management average tenure3.9yrs
Board average tenure5.8yrs

Recent management updates

Recent updates

PhaseBio Pharmaceuticals GAAP EPS of -$0.34 misses by $0.03, revenue of $0.21M misses by $0.29M

Aug 12

PhaseBio Pharmaceuticals (NASDAQ:PHAS) Has Debt But No Earnings; Should You Worry?

Aug 10
PhaseBio Pharmaceuticals (NASDAQ:PHAS) Has Debt But No Earnings; Should You Worry?

PhaseBio shares surge after inking exclusive license agreement for bentracimab

Jun 17

What Kind Of Shareholders Hold The Majority In PhaseBio Pharmaceuticals, Inc.'s (NASDAQ:PHAS) Shares?

Mar 04
What Kind Of Shareholders Hold The Majority In PhaseBio Pharmaceuticals, Inc.'s (NASDAQ:PHAS) Shares?

If You Had Bought PhaseBio Pharmaceuticals' (NASDAQ:PHAS) Shares A Year Ago You Would Be Down 28%

Jan 08
If You Had Bought PhaseBio Pharmaceuticals' (NASDAQ:PHAS) Shares A Year Ago You Would Be Down 28%

PhaseBio Pharmaceuticals EPS misses by $0.15

Nov 12

CEO Compensation Analysis

How has Jonathan Mow's remuneration changed compared to PhaseBio Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2022n/an/a

-US$103m

Mar 31 2022n/an/a

-US$115m

Dec 31 2021US$2mUS$562k

-US$131m

Sep 30 2021n/an/a

-US$118m

Jun 30 2021n/an/a

-US$112m

Mar 31 2021n/an/a

-US$111m

Dec 31 2020US$2mUS$529k

-US$99m

Sep 30 2020n/an/a

-US$80m

Jun 30 2020n/an/a

-US$66m

Mar 31 2020n/an/a

-US$47m

Dec 31 2019US$1mUS$436k

-US$39m

Sep 30 2019n/an/a

-US$33m

Jun 30 2019n/an/a

-US$29m

Mar 31 2019n/an/a

-US$27m

Dec 31 2018US$596kUS$359k

-US$24m

Sep 30 2018n/an/a

-US$22m

Jun 30 2018n/an/a

-US$16m

Mar 31 2018n/an/a

-US$12m

Dec 31 2017US$436kUS$338k

-US$10m

Compensation vs Market: Insufficient data to establish whether Jonathan's total compensation is reasonable compared to companies of similar size in the US market.

Compensation vs Earnings: Insufficient data to compare Jonathan's compensation with company performance.

CEO

Jonathan Mow (59 yo)

9.5yrs

Tenure

US$1,529,108

Compensation

Mr. Jonathan P. Mow, MBA, serves as Chief Executive Officer of Veralox Therapeutics Inc. since June 2023 and serves as its Director. He has been Chief Executive Officer of PhaseBio Pharmaceuticals, Inc. si...

Leadership Team

NamePositionTenureCompensationOwnership
Jonathan Mow
President9.5yrsUS$1.53mno data
Lawrence Perkins
Chief Restructuring Officer & Principal Financial Officer1.8yrsno datano data
Susan Arnold
Senior Vice President of Technical Operations2.9yrsno datano data
Kristopher Hanson
SVP, General Counsel & Corporate Secretary4.9yrsno datano data
Glen Burkhardt
Senior Vice President of Human Resources4.9yrsno datano data
Jonathan Birchall
Chief Commercial Officer2.8yrsno datano data

3.9yrs

Average Tenure

53.5yo

Average Age

Experienced Management: PHAS.Q's management team is considered experienced (3.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Jonathan Mow
President10yrsUS$1.53mno data
Richard van den Broek
Independent Director5.6yrsUS$82.86kno data
Edmund Harrigan
Independent Director5.8yrsUS$76.36k0.020%
$ 0.01
Clay Thorp
Independent Chairman of the Board22.7yrsUS$116.36k0.074%
$ 0.04
William Humphries
Independent Director3yrsUS$62.58k0.0051%
$ 0.002
Nancy Hutson
Independent Director6.5yrsUS$87.36k0.083%
$ 0.04
Alexander Sapir
Independent Director4.6yrsUS$77.86k0.0075%
$ 0.004

5.8yrs

Average Tenure

58yo

Average Age

Experienced Board: PHAS.Q's board of directors are considered experienced (5.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/09/12 22:59
End of Day Share Price 2024/09/12 00:00
Earnings2022/06/30
Annual Earnings2021/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

PhaseBio Pharmaceuticals, Inc. is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Andrew FeinH.C. Wainwright & Co.
Chad MesserNeedham & Company
Annabel SamimyStifel, Equities Research